Effects of Esomeprazole 40 mg Twice Daily on Asthma

Kiljander, Toni; Harding, Susan M.; Field, Stephen K.; Stein, Mark R.; Nelson, Harold S.; Ekelund, Jan; Illueca, Marta; Beckman, Ola; Sostek, Mark

doi:10.1164/rccm.200507-1167oc

Cited by 206 publications

(163 citation statements)

References 28 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…84 In a placebo-controlled study, it was found that esomeprazole 40 mg twice daily, given for 4 months, improved peak expiratory flow in 45.4% of subjects with asthma who presented with both GERD and nocturnal respiratory symptoms. 85 Conversely, a recent study of 412 patients with poorly controlled asthma, conducted by the American Lung Association Asthma Clinical Research Center, did not find any benefit for either esomeprazole 40 mg twice daily or placebo after 24 weeks of treatment. 86 Similarly, a Cochrane Review of antireflux therapy in patients with asthma found only minimal improvement of asthma symptoms with therapy.…”

Section: -74mentioning

confidence: 94%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the therapeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, maintenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett's esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any future development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the aforementioned areas of unmet need.

show abstract

Section: -74mentioning

confidence: 94%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…Harding et al [19] studied 30 asthmatic patients with GERD and showed that using omeprazole 40 mg/day for 12 weeks, did not result in improvement in any of the parameters including daytime symptoms, night-time symptoms, PEF, and FEV 1 . Kiljander et al [24] studied 322 asthmatic patients with GERD and showed that esomeprazole 80 mg/day for 16 weeks resulted in significant improvement in PEF only in patients who had night-time symptoms. The American Lung Association Asthma Clinical Research Center studied 412 partly controlled asthmatics with GERD.…”

Section: Discussionmentioning

confidence: 99%

Observational study of omeprazole for gastroesophageal reflux on pulmonary function in adult asthmatics

et al. 2015

View full text Add to dashboard Cite

Background: Asthma is a chronic inflammatory disease of airways. Gastroesophageal reflux disease (GERD) is known to be associated with worsening asthma. We hypothesized that treatment of GERD in asthmatics will improve asthma control and quality of life. We reviewed our experience of treatment of GERD in asthmatics in Thailand. Objectives: To study the effects of omeprazole for treatment of GERD in patients with poorly controlled asthma on pulmonary function tests and asthma control test (ACT) scores. Methods: This study was conducted at King Chulalongkorn Memorial Hospital between August 2009 and December 2010. Patients with partly controlled and uncontrolled asthma who were found to have GERD by 24 hour esophageal pH monitoring were administered omeprazole 40 mg per day for 8 weeks. Pulmonary function tests and ACT scores before and after treatment were compared at 4-weeks and 8-weeks follow up. Results: Twenty four patients were included in this study. None of them had asthmatic attacks during the study. After 4 and 8 weeks of omeprazole treatment, the mean FEV1 (2.20 ± 0.64 L, 2.36 ± 0.58 L, respectively) and the mean ACT score (20.82 ± 3.30, 23.00 ± 1.69, respectively) were significantly higher than the pretreatment values (mean FEV1 1.99 ± 0.56 L and ACT score 16.36 ± 3.97) (P < 0.05). Conclusion: High-dose omeprazole may improve pulmonary function and the level of asthma control in Thai patients with partly controlled or uncontrolled asthma and coexisting GERD.

show abstract

“…262 In general, benefits of proton pump inhibitors in asthma appear to be limited to patients with both symptomatic reflux and night-time respiratory symptoms. 263 Other treatment options include motility agents, lifestyle changes and fundoplication. In summary, symptomatic reflux should be treated, but patients with poorly controlled asthma should not be treated with anti-reflux therapy unless they also have symptomatic reflux (Evidence A).…”

Section: Managementmentioning

confidence: 99%